The pharmacokinetics and pharmacodynamics of immunosuppressive agents.
Designing immunosuppressive regimens for the pediatric transplant patient is challenging because one must balance the need to provide adequate immunosuppression without interfering with normal growth processes or causing long-term adverse consequences. To optimize immunosuppressive therapy and minimize toxicity, it is necessary for the nurse to be knowledgeable of the pharmacokinetic and pharmacodynamic characteristics of the various agents. It is also important to understand which drugs interact with immunosuppressive agents and how to manage these interactions.
Lake
K D
KD
Kilkenny
J M
JM
D000305:Adrenal Cortex Hormones / Q000493:pharmacokinetics / Q000494:pharmacology; D000961:Antilymphocyte Serum / Q000378:metabolism; D001379:Azathioprine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D016572:Cyclosporine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D016853:Muromonab-CD3 / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine